Nanobiotix Reports Phase 1 Response in Anti-PD-1-Resistant Melanoma
Nanobiotix announced a response in a Phase 1 study of melanoma resistant to anti-PD-1 treatment.
Nanobiotix announced a response in a Phase 1 study of melanoma resistant to anti-PD-1 treatment.